MedComm – Oncology is a peer-reviewed english-language open-access journal published by Wiley in Australia, operating under an open-access model since 2022. The journal covers Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens.
Authors are required to pay an article processing charge to publish in MedComm – Oncology; refer to the journal's APC page for the current rate. A waiver policy is offered for eligible authors. Articles are released under the CC BY license (see other journals using this license).
All submissions undergo plagiarism screening before peer review.
Keywords
cancer, gene therapy, cancer metabolism, immunotherapy, cancer biomarkers
At a glance
ISSN
- electronic
- 2769-6448
Frequently asked questions
Is MedComm – Oncology peer-reviewed?
Yes — MedComm – Oncology operates a Anonymous peer review review process.
Does MedComm – Oncology charge an article processing charge (APC)?
Yes — refer to the journal's APC page for the current rate. A waiver policy is available for eligible authors.
What subjects does MedComm – Oncology publish?
MedComm – Oncology publishes research in Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens.
What languages does MedComm – Oncology accept?
MedComm – Oncology accepts manuscripts in English.
What is the ISSN of MedComm – Oncology?
ISSN:
2769-6448 (electronic).How do I submit a manuscript to MedComm – Oncology?
Submit through the journal's official portal: visit submission page →
How long does peer review take at MedComm – Oncology?
Average time from submission to publication is approximately 15 weeks.